Direkt zum Inhalt
Merck
  • Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.

Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.

Acta pharmacologica Sinica (2011-02-01)
Chen Li, Feng Zhang, Hong Lin, Zhong-can Wang, Xin-jian Liu, Zhen-qing Feng, Jin Zhu, Xiao-hong Guan
ZUSAMMENFASSUNG

To transform the human anti-rabies virus glycoprotein (anti-RABVG) single-chain variable fragment (scFv) into a Fab fragment and to analyze its immunological activity. The Fab gene was amplified using overlap PCR and inserted into the vector pComb3XSS. The recombinant vector was then transformed into E coli Top10F' for expression and purification. The purified Fab was characterized using SDS-PAGE, Western blotting, indirect ELISA, competitive ELISA, and the fluorescent antibody virus neutralization test (FAVN), respectively, and examined in a Kunming mouse challenge model in vivo. A recombinant vector was constructed. The Fab was expressed in soluble form in E coli Top10F'. Specific binding of the Fab to rabies virus was confirmed by indirect ELISA and immunoprecipitation (IP). The neutralizing antibody titer of Fab was 10.26 IU/mL. The mouse group treated with both vaccine and human rabies immunoglobulin (HRIG)/Fab091 (32 IU/kg) showed protection against rabies, compared with the control group (P<0.05, Logrank test). The antibody fragment Fab was shown to be a neutralizing antibody against RABVG. It can be used together with other monoclonal antibodies for post-exposure prophylaxis of rabies virus in future studies.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-Human-IgG (Fab-spezifisch)−Peroxidase in Ziege hergestellte Antikörper, affinity isolated antibody